



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 16 April 2020

Re: Freedom of Information Request
Ref: 79- 2020

Thank you for your email dated the 17th March 2020, requesting information regarding the treatment of Ovarian Cancer.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Question 1

How many patients have been **diagnosed over the last 6 months with epithelial ovarian, fallopian tube or primary peritoneal cancer?

If none, do you refer ovarian cancer patients to another trust, if so which one?

****N.B - The Clatterbridge Cancer Centre NHS Foundation Trust is a specialist cancer centre and patients are referred to the Trust post diagnosis**

Tumour Group	Number
Fallopian tube	Exempt under S.40
Specified Part Peritoneum	13
Epithelial ovarian	43

Question 2

Of the ovarian patients, how many have been tested for **BRCA mutation?

If unknown please state unknown and move to Question 4

Tested for BRCA mutation	Number
Yes	13
Recently consented – result awaited	20
Not tested/Not known	10

****N.B - All patients with high grade serous/endometrioid ovarian/fallopian tube or peritoneal cancers are routinely offered testing for germline and somatic BRCA m testing.**

The Trust aim to have all results germline and somatic BRCA available for the end of first line treatment to consider maintenance PARP inhibitors.

At this stage patients could only be considered for olaparib. They are not eligible for niaraparib or rucaparib under NHS funding for maintenance first line therapy.

Question 3

Of the ovarian patient BRCA mutation tests how many tested positive?

Please note, although not all of the figures below fall within the small number data category, these figures provided in combination with the responses provided in Q2, may lead to small number data being released. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000.

BRCA mutation test results	Number
Positive	Exempt under S.40
Negative	Exempt under S.40
Recently consented – result awaited	Exempt under S.40

Question 4

Of the ovarian patients diagnosed over the last 6 months, how many have been treated with the below:

Paclitaxel in combination with a platinum-based compound = 17 patients

Platinum-based therapy alone (cisplatin or carboplatin) = 11 patients

Bevacizumab in combination with paclitaxel and carboplatin = Exempt under S.40

Olaparib = 0 patients

Niraparib = 0 patients

Rucaparib = 0 patients

Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy or in combination with a platinum-based compound = 0 patients

Question 5

Of those who were positive for a BRCA mutation, how many received Olaparib for 1st line maintenance? = 0 patients

Question 6

Of those who were positive for a BRCA mutation, how many received Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance? = Exempt under S.40

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.